Bioline Rx Ltd Adr (BLRX)

Sep 29, 2025

BioLineRx, Hemispherian AS establish joint venture to develop GLIX1 - TipRanks

Sep 29, 2025

Sep 29, 2025

BioLineRx and Hemispherian Launch Joint Venture to Develop GLIX1 for Glioblastoma - TipRanks

Sep 29, 2025

Sep 29, 2025

BioLineRx and Hemispherian form joint venture to develop brain cancer drug - Investing.com

Sep 29, 2025

Sep 29, 2025

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers - Sahm

Sep 29, 2025

Sep 20, 2025

BioLineRx (NASDAQ:BLRX) Stock Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World

Sep 20, 2025

Sep 02, 2025

BioLineRx ADR Earnings Call: Optimism Amid Challenges - MSN

Sep 02, 2025

Aug 21, 2025

Earnings call transcript: BioLineRx Q2 2025 sees restructuring and innovation - Investing.com

Aug 21, 2025

Aug 15, 2025

BioLineRx: Strategic Pipeline Expansion and Strong Financial Health Justify Buy Rating - TipRanks

Aug 15, 2025

Aug 15, 2025

BioLineRx Ltd. Reports Q2 2025 Financial Results - TipRanks

Aug 15, 2025

Aug 14, 2025

BioLineRx Reports Q2 2025 Financials and Strategic Updates - MSN

Aug 14, 2025

Aug 14, 2025

BioLineRx To Report Second Quarter 2025 Results On August 14, 2025 - Barchart.com

Aug 14, 2025

Aug 14, 2025

BioLineRx: Promising Financial Position and Strategic Initiatives Drive Buy Rating - TipRanks

Aug 14, 2025

Aug 14, 2025

BioLineRx Reports Second Quarter 2025 Financial Results And Provides Corporate Update - Barchart.com

Aug 14, 2025

Jul 25, 2025

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail

Jul 25, 2025

Jul 09, 2025

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail

Jul 09, 2025

Jul 06, 2025

Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail

Jul 06, 2025

Jun 30, 2025

BioLineRx Ltd. Approves Key Proposals at Annual Meeting - TipRanks

Jun 30, 2025

Jun 24, 2025

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Capricor Therapeutics (CAPR) and Abbott Laboratories (ABT) - The Globe and Mail

Jun 24, 2025

Jun 17, 2025

Promising Phase 2 Trial Results Drive Buy Rating for BioLine RX in mPDAC Treatment - TipRanks

Jun 17, 2025

Jun 04, 2025

BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN

Jun 04, 2025

Jun 04, 2025

Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail

Jun 04, 2025

May 31, 2025

BioLineRx upgraded to Buy from Hold at JonesResearch - Yahoo Finance

May 31, 2025

May 31, 2025

BioLineRx reports promising pancreatic cancer trial data By Investing.com - Investing.com South Africa

May 31, 2025

May 30, 2025

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating By Stocktwits - Investing.com India

May 30, 2025

May 30, 2025

BioLineRx announces new data from Phase 2 combination trial of motixafortide - TipRanks

May 30, 2025

May 30, 2025

Jones Trading raises BioLineRx stock rating, targets $12 By Investing.com - Investing.com South Africa

May 30, 2025

May 30, 2025

Jones Trading raises BioLineRx stock rating, targets $12 - Investing.com India

May 30, 2025

May 30, 2025

BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial - TipRanks

May 30, 2025

May 30, 2025

BioLineRx reports promising pancreatic cancer trial data - Investing.com

May 30, 2025

May 29, 2025

JonesTrading Reaffirms Their Hold Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail

May 29, 2025

May 28, 2025

Jones Trading maintains Hold on BioLineRx stock amid royalty prospects - Investing.com India

May 28, 2025

May 28, 2025

Jones Trading maintains Hold on BioLineRx stock amid royalty prospects By Investing.com - Investing.com South Africa

May 28, 2025

May 28, 2025

H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com

May 28, 2025

May 28, 2025

H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock By Investing.com - Investing.com South Africa

May 28, 2025

May 28, 2025

BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks

May 28, 2025

May 27, 2025

BioLineRx Ltd. Reports Q1 2025 Financial Results - TipRanks

May 27, 2025

May 27, 2025

BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident By Stocktwits - Investing.com India

May 27, 2025

May 27, 2025

BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks

May 27, 2025

May 27, 2025

Options Volatility and Implied Earnings Moves Today, May 27, 2025 - TipRanks

May 27, 2025

May 23, 2025

BioLineRx Ltd. Schedules Annual Shareholder Meeting for June 2025 - TipRanks

May 23, 2025

May 17, 2025

Analysts’ Top Healthcare Picks: Bicara Therapeutics Inc. (BCAX), Fulcrum Therapeutics (FULC) - The Globe and Mail

May 17, 2025

May 09, 2025

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail

May 09, 2025

Apr 01, 2025

BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com

Apr 01, 2025

Apr 01, 2025

BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks

Apr 01, 2025

Mar 31, 2025

BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks

Mar 31, 2025

Mar 31, 2025

Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail

Mar 31, 2025

Mar 31, 2025

BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks

Mar 31, 2025

Jan 31, 2025

BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com

Jan 31, 2025

Jan 21, 2025

BioLineRx announces strategic shift with licensing deals - Investing.com

Jan 21, 2025